about
Ferrocene-based antimalarialsSimilar Biological Activities of Two Isostructural Ruthenium and Osmium ComplexesA ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome coreRuthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozymeHydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsAnionic chlorido(triphenyl)tin(IV) bearing N-phthaloylglycinato or 1,2,4-benzenetricarboxylato 1,2-anhydride ligands: potential cytotoxic and apoptosis-inducing agents against several types of cancer.Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocyclesMass spectrometry and UV-VIS spectrophotometry of ruthenium(II) [RuClCp(mPTA)2](OSO2CF3)2 complex in solution.DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.Gas-phase ion/ion reactions of transition metal complex cations with multiply charged oligodeoxynucleotide anions.Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems.Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitroLibrary of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.Picazoplatin, an azide-containing platinum(II) derivative for target analysis by click chemistry.The effect of novel rhenium compounds on lymphosarcoma, PC-3 prostate and myeloid leukemia cancer cell lines and an investigation on the DNA binding properties of one of these compounds through electronic spectroscopy.Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSNovel C,N-chelate rhodium(III) and iridium(III) antitumor complexes incorporating a lipophilic steroidal conjugate and their interaction with DNA.Organometallic anticancer compoundsRuthenium polypyridyl complexes and their modes of interaction with DNA: is there a correlation between these interactions and the antitumor activity of the compounds?Coordination Driven Self-Assembly and Anticancer Activity of Molecular Rectangles Containing Octahedral Ruthenium Metal Centers.Self-assembly of Cationic, Hetero- or Homo-nuclear Ru(II) Macrocyclic Rectangles and their Photophysical, Electrochemical and Biological Studies.New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents.Cytotoxicity of a Ti(IV) compound is independent of serum proteinsAnticancer activities of self-assembled molecular bowls containing a phenanthrene-based donor and Ru(II) acceptors.Synthesis and cyclometalation of a pyrido[3,2-e]-2,10b-diaza-cyclopenta[c]fluorene-1,3-dione scaffold.New trends for metal complexes with anticancer activitySynthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine.Dual mode of cell death upon the photo-irradiation of a RuII polypyridyl complex in interphase or mitosis.Bioorganometallic chemistry--from teaching paradigms to medicinal applications.Application of metal coordination chemistry to explore and manipulate cell biology.Metal-organic frameworks as potential drug carriers.A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action.Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.Metal-organic frameworks as potential drug delivery systems.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Atomistic-level portrayal of drug-DNA Interplay: a history of courtships and meetings revealed by molecular simulations.A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin.
P2860
Q21032535-92C84387-84EB-4A2D-88FE-1D50B86A9E34Q27650404-B2AB0AE6-D3DC-4E48-A520-71B02270E85DQ27666776-F367D80F-876F-4101-AD34-5605C57F242EQ27689147-56637E72-D8E9-467C-8A7A-70D54E161F84Q28834484-CFD651C1-94E3-45A6-9417-C0ABE4B8A592Q30313823-70B6A518-E0A5-4908-99E1-19D5C82DD85EQ30623124-FC36CD26-CC41-4A1C-97BC-3D253D21C958Q30879929-56FB0729-F14F-48CC-BF5A-350CCB7553BDQ31043552-B330E0CD-B2AA-46F4-9D9B-3AD012273E71Q33310555-35D08640-5017-4052-860E-63D060B0C2F4Q33953543-3325D656-D2C3-4179-B36C-5A8645904609Q33955538-4E439E96-7B41-4025-A7F1-4B8F662A8C2BQ33991566-1C8C99E5-2269-46A7-B170-063C3B2558F7Q34033965-58F960C2-832B-4A27-B2F8-AE6E80AE7F94Q34159608-C950656B-02A1-46F6-97D8-FC0497B95339Q34327703-08FB958C-506C-44F7-85E7-1DD6D6323186Q34394993-1988115C-EA22-42B2-B973-C60932CD2EF8Q34415646-5F8FA9D3-5842-4AD9-BC22-1C5C0797DFD7Q34476685-5CEA5738-5F77-4500-A928-B64EFE6A935AQ34565192-E8CBD005-EB35-4454-BEB7-7399939385D0Q35110527-E553CCBE-7EA8-4DF5-8875-5BB0DA093F71Q35615395-3D4815CB-11C9-4643-B964-D0CFC26C324FQ35822254-B3F46C31-CFD5-4099-97BC-286EF0A2AE5EQ35882449-B9DAA7FA-A653-4509-BED2-7F0DC52F55D0Q36010364-150AA3E2-C807-4069-9FA8-E36517C1EE24Q36076311-B2AD519B-DB25-4FC1-82C6-DAA670454E5CQ37044080-128D2AF9-FB22-49CE-8CCB-408367B24D42Q37169192-970AB686-AAB6-4004-96CD-0E5BA762A6F5Q37274934-1CBACEA4-496D-49A5-9734-1190AFC27CD8Q37377528-DD2F203E-8B38-4838-A7F5-A0C90C19248BQ37387617-1A501819-4964-440C-B5C6-1DF17546F87FQ37673478-05622876-8CE4-4B40-80FE-18B9C45FED1AQ37709331-65630E1C-F728-4FBA-878B-A98CC0857E79Q37729331-3B48AC5F-E3C5-4E48-9B6D-6242AC954DACQ37855894-988F8CC8-27CA-4395-97BB-80EC03EB2170Q38011996-C0B1848F-8BF2-4D34-8BA0-27AAB37588E9Q38058895-3EC7EC84-CD81-476A-8F23-B843058276BBQ38105454-1D4454CE-1A65-4E66-B640-BEEF8D208E7BQ38237566-236B230D-92E3-4DEF-9FCC-859109E53F5FQ38294800-4F726897-2931-4274-AC34-72F00A45DC62
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Metal-based antitumour drugs in the post genomic era.
@ast
Metal-based antitumour drugs in the post genomic era.
@en
type
label
Metal-based antitumour drugs in the post genomic era.
@ast
Metal-based antitumour drugs in the post genomic era.
@en
prefLabel
Metal-based antitumour drugs in the post genomic era.
@ast
Metal-based antitumour drugs in the post genomic era.
@en
P356
P1433
P1476
Metal-based antitumour drugs in the post genomic era.
@en
P304
P356
10.1039/B601840H
P407
P577
2006-03-28T00:00:00Z